logo
Twitter
Discord
Email
logo
CRISPR Therapeutics AG

CRISPR Therapeutics AG

NASDAQ•CRSP
CEO: Dr. Samarth Kulkarni Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2016-10-19
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Contact Information
Baarerstrasse 14, Zug, 6300, Switzerland
41-41-561-32-77
www.crisprtx.com
Market Cap
$5.09B
P/E (TTM)
-10.8
45.1
Dividend Yield
--
52W High
$78.48
52W Low
$30.04
52W Range
58%
Rank58Top 74.6%
2.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$889.00K+47.67%
4-Quarter Trend

EPS

-$1.17+15.84%
4-Quarter Trend

FCF

-$84.71M-20.93%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Grant Revenue Growth Grant revenue reached $2.65M for nine months 2025, up $1.02M compared to $1.62M in 2024, showing revenue increase.
Cash Position Strengthened Cash, equivalents, restricted cash totaled $298.02M as of September 30, 2025, showing a $60.83M increase from prior year.
R&D Spending Down Nine-month R&D expenses fell $37.22M to $201.28M, driven primarily by decreased headcount and lower external costs.
CASGEVY Collaboration Costs Collaboration expense net rose $49.53M to $159.78M for nine months, reflecting increased operational share for CASGEVY.

Risk Factors

Government Agency Disruption FDA/SEC shutdowns or staffing changes could hinder hiring, slow product development, and delay normal business functions.
Continued Operating Losses Nine-month net loss reached $(450.99M); expect continued losses requiring external financing, risking shareholder dilution.
Intellectual Property Litigation Potential adverse impact from ongoing or future lawsuits concerning intellectual property rights and related legal proceedings.
Market Volatility Risk Highly volatile common share trading prices create difficulties when raising necessary capital on favorable terms.

Outlook

Cash Runway Secured Existing cash resources expected to fund operating expenses and capital expenditures for a minimum of 24 months.
Future Financing Plans Intend to consider additional financing opportunities, such as equity or debt, when market conditions become favorable.
CTX310 Clinical Advancement Advancing CTX310 into Phase 1b clinical trials, prioritizing development in sHTG and mixed dyslipidemia indications.
Next-Gen Editing Innovation CRISPR-X team focuses on innovating next-generation editing modalities, including whole gene correction via non-viral delivery.

Peer Comparison

Revenue (TTM)

PTC Therapeutics, Inc.PTCT
$1.78B
+97.5%
Axsome Therapeutics, Inc.AXSM
$561.26M
+65.8%
Rhythm Pharmaceuticals, Inc.RYTM
$174.33M
+54.9%

Gross Margin (Latest Quarter)

Axsome Therapeutics, Inc.AXSM
93.0%
+1.1pp
PTC Therapeutics, Inc.PTCT
92.5%
-2.0pp
Rhythm Pharmaceuticals, Inc.RYTM
89.3%
+0.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RNA$9.39B-20.3-33.5%0.4%
CYTK$7.92B-10.6232.9%72.3%
NUVL$7.77B-20.2-39.5%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-70.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $889.00K+47.7%
    |
    EPS: $-1.17+15.8%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-2.40+61.1%
    N/A
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $865.00K+71.6%
    |
    EPS: $-1.58+10.5%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 11, 2025|
    Revenue: $35.00M-90.6%
    |
    EPS: $-4.34-123.7%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $602.00K+0.0%
    |
    EPS: $-1.01-28.4%
    Meet
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 5, 2024|
    Revenue: $517.00K-99.3%
    |
    EPS: $-1.49+52.0%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $504.00K-99.5%
    |
    EPS: $-1.43+113.4%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $371.21M+85039.0%
    |
    EPS: $-1.94+76.8%
    Miss